Aethlon Medical Inc. Announces New Hemopurifier® Patent Issuances for Long COVID and COVID-19-Associated Coagulopathy Treatment

Reuters

2025/09/03

<a href="https://laohu8.com/S/AEMD">Aethlon Medical Inc</a>. Announces New Hemopurifier® Patent Issuances for Long COVID and COVID-19-Associated Coagulopathy Treatment

Aethlon Medical Inc. has announced the issuance of two patents related to the use of its Hemopurifier® for the treatment of Long COVID and COVID-19-associated coagulopathy $(CAC)$. U.S. Patent No. 12,409,260, which is set to be issued on September 9, 2025, covers the treatment of Long COVID by removing circulating COVID-19 spike protein in patients exhibiting symptoms for more than 12 weeks post-infection. Unitary European Patent 4136453, which was issued on July 9, 2025, pertains to the treatment of COVID-19-associated CAC in patients without circulating viral particles. These patents aim to strengthen the company's intellectual property portfolio in addressing significant unmet medical needs. The U.S. patent will expire in 2042, while the European patent will expire in 2041.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aethlon Medical Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA62338) on September 03, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2564007398"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2564007398\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2564007398?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-03 20:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2564007398","market":"fut","top_or_hot":-1,"title":"Aethlon Medical Inc. Announces New Hemopurifier® Patent Issuances for Long COVID and COVID-19-Associated Coagulopathy Treatment","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/AEMD\">Aethlon Medical Inc</a>. Announces New Hemopurifier® Patent Issuances for Long COVID and COVID-19-Associated Coagulopathy Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Aethlon Medical Inc. has announced the issuance of two patents related to the use of its Hemopurifier® for the treatment of Long COVID and COVID-19-associated coagulopathy <a href=\"https://laohu8.com/S/CAC\">$(CAC)$</a>. U.S. Patent No. 12,409,260, which is set to be issued on September 9, 2025, covers the treatment of Long COVID by removing circulating COVID-19 spike protein in patients exhibiting symptoms for more than 12 weeks post-infection. Unitary European Patent 4136453, which was issued on July 9, 2025, pertains to the treatment of COVID-19-associated CAC in patients without circulating viral particles. These patents aim to strengthen the company's intellectual property portfolio in addressing significant unmet medical needs. The U.S. patent will expire in 2042, while the European patent will expire in 2041.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aethlon Medical Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA62338) on September 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aethlon Medical Inc. Announces New Hemopurifier® Patent Issuances for Long COVID and COVID-19-Associated Coagulopathy Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAethlon Medical Inc. Announces New Hemopurifier® Patent Issuances for Long COVID and COVID-19-Associated Coagulopathy Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-03 20:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/AEMD\">Aethlon Medical Inc</a>. Announces New Hemopurifier® Patent Issuances for Long COVID and COVID-19-Associated Coagulopathy Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Aethlon Medical Inc. has announced the issuance of two patents related to the use of its Hemopurifier® for the treatment of Long COVID and COVID-19-associated coagulopathy <a href=\"https://laohu8.com/S/CAC\">$(CAC)$</a>. U.S. Patent No. 12,409,260, which is set to be issued on September 9, 2025, covers the treatment of Long COVID by removing circulating COVID-19 spike protein in patients exhibiting symptoms for more than 12 weeks post-infection. Unitary European Patent 4136453, which was issued on July 9, 2025, pertains to the treatment of COVID-19-associated CAC in patients without circulating viral particles. These patents aim to strengthen the company's intellectual property portfolio in addressing significant unmet medical needs. The U.S. patent will expire in 2042, while the European patent will expire in 2041.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aethlon Medical Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA62338) on September 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AEMD","symbol_name":"Aethlon Medical Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250903:nNDL7gSqwK:1","article_id":"2564007398","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2564007398","pubTimestamp":1756900997,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Aethlon Medical Inc. Announces New Hemopurifier Patent Issuances for Long COVID and COVID-19-Associated Coagulopathy Treatment. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aethlon Medical Inc. published the original content used to generate this news brief via PR Newswire  on September 03, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AEMD":"Aethlon Medical Inc","BK4568":"美国抗疫概念","BK4082":"医疗保健设备","BK4583":"猴痘概念"},"translate_title":"Aethlon Medical Inc.宣布推出新型血液净化器®新冠后遗症病和COVID-19相关凝血病治疗的专利发布","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AEMD":0.9},"content_text":"Aethlon Medical Inc. Announces New Hemopurifier® Patent Issuances for Long COVID and COVID-19-Associated Coagulopathy Treatment\n    \n\n        Aethlon Medical Inc. has announced the issuance of two patents related to the use of its Hemopurifier® for the treatment of Long COVID and COVID-19-associated coagulopathy $(CAC)$. U.S. Patent No. 12,409,260, which is set to be issued on September 9, 2025, covers the treatment of Long COVID by removing circulating COVID-19 spike protein in patients exhibiting symptoms for more than 12 weeks post-infection. Unitary European Patent 4136453, which was issued on July 9, 2025, pertains to the treatment of COVID-19-associated CAC in patients without circulating viral particles. These patents aim to strengthen the company's intellectual property portfolio in addressing significant unmet medical needs. The U.S. patent will expire in 2042, while the European patent will expire in 2041.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aethlon Medical Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA62338) on September 03, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}